25 XP   0   0   10

Ceapro
Buy, Hold or Sell?

Let's analyse Ceapro together

PenkeI guess you are interested in Ceapro. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Ceapro. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Ceapro

I send you an email if I find something interesting about Ceapro.

Quick analysis of Ceapro (30 sec.)










What can you expect buying and holding a share of Ceapro? (30 sec.)

How much money do you get?

How much money do you get?
C$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
C$0.38
Expected worth in 1 year
C$0.36
How sure are you?
72.5%

+ What do you gain per year?

Total Gains per Share
C$-0.02
Return On Investment
-8.3%

For what price can you sell your share?

Current Price per Share
C$0.26
Expected price per share
C$0.23 - C$0.27
How sure are you?
50%

1. Valuation of Ceapro (5 min.)




Live pricePrice per Share (EOD)

C$0.26

Intrinsic Value Per Share

C$-1.07 - C$0.34

Total Value Per Share

C$-0.68 - C$0.72

2. Growth of Ceapro (5 min.)




Is Ceapro growing?

Current yearPrevious yearGrowGrow %
How rich?$21.9m$21.8m$1m4.8%

How much money is Ceapro making?

Current yearPrevious yearGrowGrow %
Making money-$494.2k$968.6k-$1.4m-296.0%
Net Profit Margin-29.0%26.7%--

How much money comes from the company's main activities?

3. Financial Health of Ceapro (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#560 / 1010

Most Revenue
#267 / 1010

Most Profit
#121 / 1010

Most Efficient
#68 / 1010

What can you expect buying and holding a share of Ceapro? (5 min.)

Welcome investor! Ceapro's management wants to use your money to grow the business. In return you get a share of Ceapro.

What can you expect buying and holding a share of Ceapro?

First you should know what it really means to hold a share of Ceapro. And how you can make/lose money.

Speculation

The Price per Share of Ceapro is C$0.26. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Ceapro.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Ceapro, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is C$0.38. Based on the TTM, the Book Value Change Per Share is C$-0.01 per quarter. Based on the YOY, the Book Value Change Per Share is C$0.02 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is C$0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Ceapro.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 C$% of Price per ShareC$% of Price per ShareC$% of Price per ShareC$% of Price per ShareC$% of Price per Share
Usd Eps-0.01-3.7%-0.01-4.0%0.014.7%0.000.7%0.001.1%
Usd Book Value Change Per Share-0.01-3.5%0.00-1.5%0.014.8%0.001.3%0.012.7%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.01-3.5%0.00-1.5%0.014.8%0.001.3%0.012.7%
Usd Price Per Share0.27-0.37-0.44-0.37-0.42-
Price to Earnings Ratio-6.96--8.82-10.67-4.15-51.33-
Price-to-Total Gains Ratio-29.54--47.99-41.87-21.25-22.91-
Price to Book Ratio0.97-1.27-1.57-1.51-5.01-
Price-to-Total Gains Ratio-29.54--47.99-41.87-21.25-22.91-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.190216
Number of shares5257
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.000.00
Usd Total Gains Per Share0.000.00
Gains per Quarter (5257 shares)-20.7617.81
Gains per Year (5257 shares)-83.0471.23
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-83-9307161
20-166-1760142132
30-249-2590214203
40-332-3420285274
50-415-4250356345
60-498-5080427416
70-581-5910499487
80-664-6740570558
90-747-7570641629
100-830-8400712700

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%7.05.00.058.3%12.08.00.060.0%26.014.00.065.0%47.060.00.043.9%
Book Value Change Per Share1.03.00.025.0%8.04.00.066.7%13.07.00.065.0%29.011.00.072.5%61.045.01.057.0%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.0107.00.0%
Total Gains per Share1.03.00.025.0%8.04.00.066.7%13.07.00.065.0%29.011.00.072.5%61.045.01.057.0%

Fundamentals of Ceapro

About Ceapro

Ceapro Inc., a biotechnology company, engages in the development and marketing of health and wellness products and technology relating to plant extracts in the United States, Germany, China, Canada, and internationally. The company is involved in the development of proprietary extraction technologies and the application of these technologies to the production, development, and commercialization of active ingredients, such as oat beta glucan and avenanthramides, which are derived from oats and other renewable plant resources for healthcare and cosmetic industries. It also offers natural active ingredients, including oat powder, oat oil, oat peptides, and lupin peptides to the personal care, cosmetic, medical, and animal health industries; anti-aging skincare products to the cosmeceutical industries; and veterinary therapeutic products, including an oat shampoo, an ear cleanser, and a dermal complex/conditioner. The company has a research collaboration with the Angiogenesis Foundation. The company was incorporated in 1997 and is headquartered in Edmonton, Canada.

Fundamental data was last updated by Penke on 2024-04-21 02:03:06.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is fair priced.

1.1. Profitability of Ceapro.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Ceapro earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Ceapro to the Biotechnology industry mean.
  • A Net Profit Margin of -39.7% means that $-0.40 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Ceapro:

  • The MRQ is -39.7%. The company is making a huge loss. -2
  • The TTM is -29.0%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-39.7%TTM-29.0%-10.7%
TTM-29.0%YOY26.7%-55.7%
TTM-29.0%5Y2.2%-31.2%
5Y2.2%10Y7.0%-4.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-39.7%-207.2%+167.5%
TTM-29.0%-216.8%+187.8%
YOY26.7%-282.3%+309.0%
5Y2.2%-436.8%+439.0%
10Y7.0%-597.3%+604.3%
1.1.2. Return on Assets

Shows how efficient Ceapro is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Ceapro to the Biotechnology industry mean.
  • -3.1% Return on Assets means that Ceapro generated $-0.03 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Ceapro:

  • The MRQ is -3.1%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -1.9%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-3.1%TTM-1.9%-1.1%
TTM-1.9%YOY4.0%-5.9%
TTM-1.9%5Y1.0%-2.9%
5Y1.0%10Y2.2%-1.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.1%-13.3%+10.2%
TTM-1.9%-12.8%+10.9%
YOY4.0%-11.6%+15.6%
5Y1.0%-13.8%+14.8%
10Y2.2%-15.6%+17.8%
1.1.3. Return on Equity

Shows how efficient Ceapro is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Ceapro to the Biotechnology industry mean.
  • -3.5% Return on Equity means Ceapro generated $-0.03 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Ceapro:

  • The MRQ is -3.5%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -2.2%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-3.5%TTM-2.2%-1.3%
TTM-2.2%YOY4.4%-6.6%
TTM-2.2%5Y1.1%-3.3%
5Y1.1%10Y5.3%-4.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.5%-16.9%+13.4%
TTM-2.2%-16.1%+13.9%
YOY4.4%-14.9%+19.3%
5Y1.1%-19.3%+20.4%
10Y5.3%-20.1%+25.4%

1.2. Operating Efficiency of Ceapro.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Ceapro is operating .

  • Measures how much profit Ceapro makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Ceapro to the Biotechnology industry mean.
  • An Operating Margin of -52.6% means the company generated $-0.53  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Ceapro:

  • The MRQ is -52.6%. The company is operating very inefficient. -2
  • The TTM is -35.1%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-52.6%TTM-35.1%-17.5%
TTM-35.1%YOY30.3%-65.3%
TTM-35.1%5Y3.2%-38.3%
5Y3.2%10Y9.5%-6.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-52.6%-298.0%+245.4%
TTM-35.1%-238.5%+203.4%
YOY30.3%-288.4%+318.7%
5Y3.2%-486.2%+489.4%
10Y9.5%-628.4%+637.9%
1.2.2. Operating Ratio

Measures how efficient Ceapro is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 1.57 means that the operating costs are $1.57 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Ceapro:

  • The MRQ is 1.569. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.395. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.569TTM1.395+0.174
TTM1.395YOY0.715+0.680
TTM1.3955Y0.959+0.436
5Y0.95910Y0.889+0.070
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.5693.235-1.666
TTM1.3953.310-1.915
YOY0.7153.838-3.123
5Y0.9595.679-4.720
10Y0.8897.823-6.934

1.3. Liquidity of Ceapro.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Ceapro is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 11.00 means the company has $11.00 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Ceapro:

  • The MRQ is 10.996. The company is very able to pay all its short-term debts. +2
  • The TTM is 14.229. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ10.996TTM14.229-3.233
TTM14.229YOY17.422-3.193
TTM14.2295Y9.874+4.355
5Y9.87410Y5.991+3.884
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ10.9963.863+7.133
TTM14.2294.169+10.060
YOY17.4225.337+12.085
5Y9.8746.122+3.752
10Y5.9916.434-0.443
1.3.2. Quick Ratio

Measures if Ceapro is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Ceapro to the Biotechnology industry mean.
  • A Quick Ratio of 7.59 means the company can pay off $7.59 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Ceapro:

  • The MRQ is 7.585. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 10.526. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ7.585TTM10.526-2.941
TTM10.526YOY14.957-4.431
TTM10.5265Y8.069+2.457
5Y8.06910Y4.865+3.204
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ7.5853.504+4.081
TTM10.5263.991+6.535
YOY14.9575.371+9.586
5Y8.0696.088+1.981
10Y4.8656.395-1.530

1.4. Solvency of Ceapro.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Ceapro assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Ceapro to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.12 means that Ceapro assets are financed with 11.7% credit (debt) and the remaining percentage (100% - 11.7%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Ceapro:

  • The MRQ is 0.117. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.122. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.117TTM0.122-0.005
TTM0.122YOY0.108+0.015
TTM0.1225Y0.142-0.020
5Y0.14210Y0.293-0.151
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1170.339-0.222
TTM0.1220.337-0.215
YOY0.1080.271-0.163
5Y0.1420.368-0.226
10Y0.2930.388-0.095
1.4.2. Debt to Equity Ratio

Measures if Ceapro is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Ceapro to the Biotechnology industry mean.
  • A Debt to Equity ratio of 13.3% means that company has $0.13 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Ceapro:

  • The MRQ is 0.133. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.140. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.133TTM0.140-0.007
TTM0.140YOY0.121+0.019
TTM0.1405Y0.167-0.027
5Y0.16710Y1.366-1.198
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1330.392-0.259
TTM0.1400.403-0.263
YOY0.1210.335-0.214
5Y0.1670.427-0.260
10Y1.3660.461+0.905

2. Market Valuation of Ceapro

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Ceapro generates.

  • Above 15 is considered overpriced but always compare Ceapro to the Biotechnology industry mean.
  • A PE ratio of -6.96 means the investor is paying $-6.96 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Ceapro:

  • The EOD is -4.891. Based on the earnings, the company is expensive. -2
  • The MRQ is -6.961. Based on the earnings, the company is expensive. -2
  • The TTM is -8.819. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-4.891MRQ-6.961+2.069
MRQ-6.961TTM-8.819+1.858
TTM-8.819YOY10.671-19.490
TTM-8.8195Y4.151-12.970
5Y4.15110Y51.334-47.184
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-4.891-2.300-2.591
MRQ-6.961-2.656-4.305
TTM-8.819-2.718-6.101
YOY10.671-4.145+14.816
5Y4.151-6.258+10.409
10Y51.334-6.315+57.649
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Ceapro:

  • The EOD is 90.275. Based on how much money comes from the company's main activities, the company is overpriced. -1
  • The MRQ is 128.468. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is 30.529. Based on how much money comes from the company's main activities, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD90.275MRQ128.468-38.193
MRQ128.468TTM30.529+97.939
TTM30.529YOY11.645+18.884
TTM30.5295Y33.600-3.071
5Y33.60010Y51.396-17.797
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD90.275-2.974+93.249
MRQ128.468-3.306+131.774
TTM30.529-3.508+34.037
YOY11.645-5.613+17.258
5Y33.600-8.378+41.978
10Y51.396-8.873+60.269
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Ceapro is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 0.97 means the investor is paying $0.97 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Ceapro:

  • The EOD is 0.679. Based on the equity, the company is cheap. +2
  • The MRQ is 0.967. Based on the equity, the company is cheap. +2
  • The TTM is 1.268. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD0.679MRQ0.967-0.287
MRQ0.967TTM1.268-0.302
TTM1.268YOY1.569-0.301
TTM1.2685Y1.512-0.243
5Y1.51210Y5.011-3.499
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.6791.914-1.235
MRQ0.9672.116-1.149
TTM1.2682.097-0.829
YOY1.5692.881-1.312
5Y1.5123.550-2.038
10Y5.0113.936+1.075
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Ceapro compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.013-0.005-57%0.017-173%0.005-371%0.009-232%
Book Value Per Share--0.3830.400-4%0.380+1%0.339+13%0.248+54%
Current Ratio--10.99614.229-23%17.422-37%9.874+11%5.991+84%
Debt To Asset Ratio--0.1170.122-4%0.108+9%0.142-17%0.293-60%
Debt To Equity Ratio--0.1330.140-5%0.121+10%0.167-21%1.366-90%
Dividend Per Share----0%-0%-0%-0%
Eps---0.013-0.014+8%0.017-179%0.003-619%0.004-438%
Free Cash Flow Per Share--0.001-0.004+674%0.018-96%0.006-88%0.001-34%
Free Cash Flow To Equity Per Share--0.000-0.005+1635%0.018-102%0.005-107%0.005-107%
Gross Profit Margin--1.0111.029-2%0.992+2%1.002+1%1.008+0%
Intrinsic Value_10Y_max--0.342--------
Intrinsic Value_10Y_min---1.067--------
Intrinsic Value_1Y_max--0.027--------
Intrinsic Value_1Y_min---0.015--------
Intrinsic Value_3Y_max--0.087--------
Intrinsic Value_3Y_min---0.124--------
Intrinsic Value_5Y_max--0.153--------
Intrinsic Value_5Y_min---0.321--------
Market Cap20356232.000-42%28968484.00039929532.000-27%46710228.190-38%40159669.821-28%45515338.261-36%
Net Profit Margin---0.397-0.290-27%0.267-249%0.022-1910%0.070-665%
Operating Margin---0.526-0.351-33%0.303-274%0.032-1722%0.095-655%
Operating Ratio--1.5691.395+12%0.715+119%0.959+63%0.889+76%
Pb Ratio0.679-42%0.9671.268-24%1.569-38%1.512-36%5.011-81%
Pe Ratio-4.891+30%-6.961-8.819+27%10.671-165%4.151-268%51.334-114%
Price Per Share0.260-42%0.3700.510-27%0.595-38%0.512-28%0.581-36%
Price To Free Cash Flow Ratio90.275-42%128.46830.529+321%11.645+1003%33.600+282%51.396+150%
Price To Total Gains Ratio-20.756+30%-29.538-47.987+62%41.870-171%21.253-239%22.909-229%
Quick Ratio--7.58510.526-28%14.957-49%8.069-6%4.865+56%
Return On Assets---0.031-0.019-36%0.040-177%0.010-421%0.022-238%
Return On Equity---0.035-0.022-37%0.044-178%0.011-422%0.053-166%
Total Gains Per Share---0.013-0.005-57%0.017-173%0.005-371%0.009-232%
Usd Book Value--21921201.49222905787.858-4%21806669.146+1%19426629.197+13%14246736.550+54%
Usd Book Value Change Per Share---0.009-0.004-57%0.013-173%0.003-371%0.007-232%
Usd Book Value Per Share--0.2800.293-4%0.278+1%0.248+13%0.182+54%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.010-0.011+8%0.012-179%0.002-619%0.003-438%
Usd Free Cash Flow--41242.487-236725.092+674%1060137.417-96%343119.120-88%63490.607-35%
Usd Free Cash Flow Per Share--0.001-0.003+674%0.013-96%0.004-88%0.001-34%
Usd Free Cash Flow To Equity Per Share--0.000-0.004+1635%0.013-102%0.003-107%0.003-107%
Usd Market Cap14892619.331-42%21193342.89429212445.611-27%34173202.944-38%29380814.441-28%33299021.471-36%
Usd Price Per Share0.190-42%0.2710.373-27%0.435-38%0.374-28%0.425-36%
Usd Profit---761198.341-494205.311-35%968649.740-179%213193.215-457%258662.685-394%
Usd Revenue--1916040.6472067639.872-7%3489616.407-45%2797858.429-32%2400946.224-20%
Usd Total Gains Per Share---0.009-0.004-57%0.013-173%0.003-371%0.007-232%
 EOD+4 -4MRQTTM+12 -22YOY+7 -275Y+10 -2410Y+11 -23

3.2. Fundamental Score

Let's check the fundamental score of Ceapro based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-4.891
Price to Book Ratio (EOD)Between0-10.679
Net Profit Margin (MRQ)Greater than0-0.397
Operating Margin (MRQ)Greater than0-0.526
Quick Ratio (MRQ)Greater than17.585
Current Ratio (MRQ)Greater than110.996
Debt to Asset Ratio (MRQ)Less than10.117
Debt to Equity Ratio (MRQ)Less than10.133
Return on Equity (MRQ)Greater than0.15-0.035
Return on Assets (MRQ)Greater than0.05-0.031
Total5/10 (50.0%)

3.3. Technical Score

Let's check the technical score of Ceapro based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5062.119
Ma 20Greater thanMa 500.246
Ma 50Greater thanMa 1000.231
Ma 100Greater thanMa 2000.213
OpenGreater thanClose0.245
Total3/5 (60.0%)



Latest Balance Sheet

Balance Sheet of 2023-09-30. Currency in CAD. All numbers in thousands.

Summary
Total Assets33,944
Total Liabilities3,981
Total Stockholder Equity29,963
 As reported
Total Liabilities 3,981
Total Stockholder Equity+ 29,963
Total Assets = 33,944

Assets

Total Assets33,944
Total Current Assets18,006
Long-term Assets15,938
Total Current Assets
Cash And Cash Equivalents 11,356
Net Receivables 1,065
Inventory 5,371
Other Current Assets 214
Total Current Assets  (as reported)18,006
Total Current Assets  (calculated)18,006
+/-0
Long-term Assets
Property Plant Equipment 14,996
Intangible Assets 10
Long-term Assets Other 932
Long-term Assets  (as reported)15,938
Long-term Assets  (calculated)15,938
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities1,637
Long-term Liabilities2,343
Total Stockholder Equity29,963
Total Current Liabilities
Short-term Debt 391
Accounts payable 1,246
Other Current Liabilities 1,246
Total Current Liabilities  (as reported)1,637
Total Current Liabilities  (calculated)2,884
+/- 1,246
Long-term Liabilities
Capital Lease Obligations 2,345
Long-term Liabilities  (as reported)2,343
Long-term Liabilities  (calculated)2,345
+/- 1
Total Stockholder Equity
Common Stock16,722
Retained Earnings 8,300
Other Stockholders Equity 4,941
Total Stockholder Equity (as reported)29,963
Total Stockholder Equity (calculated)29,963
+/-0
Other
Capital Stock16,722
Cash and Short Term Investments 11,356
Common Stock Shares Outstanding 78,291
Current Deferred Revenue-1,246
Liabilities and Stockholders Equity 33,944
Net Debt -9,011
Net Invested Capital 29,963
Net Working Capital 16,368
Property Plant and Equipment Gross 28,087
Short Long Term Debt Total 2,345



Balance Sheet

Currency in CAD. All numbers in thousands.

 Trend2023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-12-312007-09-302007-06-302007-03-312006-12-312006-09-302006-06-302006-03-312005-12-312005-09-302005-06-302005-03-312004-12-312004-09-302004-06-302004-03-312003-12-312003-09-302003-06-302003-03-312002-12-312002-09-302002-06-302002-03-312001-12-312001-09-302001-06-302001-03-312000-12-312000-09-302000-06-302000-03-311999-12-311999-09-301999-06-301999-03-311998-12-311998-09-301998-06-301998-03-311997-12-311997-09-301997-06-301997-03-31
> Total Assets 
45,400
35,000
34,600
13,100
12,900
13,100
6,600
500
600
500
500
300
400
500
546
294
427
443
458
373
428
614
566
645
780
857
1,120
1,255
1,251
1,581
1,236
1,718
1,860
1,823
1,510
2,419
2,534
2,543
1,985
2,063
2,361
5,346
4,453
4,588
4,198
3,732
3,399
3,287
3,220
3,332
3,270
2,771
2,827
2,683
2,884
2,820
3,120
3,103
3,061
4,171
4,265
3,721
4,089
3,886
3,612
3,459
3,242
5,097
5,737
7,166
7,158
7,683
8,339
9,571
10,924
15,703
16,596
17,379
26,172
26,392
26,753
27,024
27,351
27,808
27,291
27,386
25,628
25,325
28,009
27,357
27,477
27,269
27,917
28,915
29,155
29,224
29,429
30,132
31,189
30,528
32,522
34,768
35,787
37,734
36,647
34,482
33,944
33,94434,48236,64737,73435,78734,76832,52230,52831,18930,13229,42929,22429,15528,91527,91727,26927,47727,35728,00925,32525,62827,38627,29127,80827,35127,02426,75326,39226,17217,37916,59615,70310,9249,5718,3397,6837,1587,1665,7375,0973,2423,4593,6123,8864,0893,7214,2654,1713,0613,1033,1202,8202,8842,6832,8272,7713,2703,3323,2203,2873,3993,7324,1984,5884,4535,3462,3612,0631,9852,5432,5342,4191,5101,8231,8601,7181,2361,5811,2511,2551,1208577806455666144283734584434272945465004003005005006005006,60013,10012,90013,10034,60035,00045,400
   > Total Current Assets 
5,100
3,600
3,300
300
300
400
300
200
300
200
200
200
300
400
426
181
320
342
363
273
333
521
479
372
394
477
759
908
906
1,220
637
933
1,105
1,104
832
1,739
1,880
1,915
1,265
1,284
1,543
3,933
2,428
2,277
1,765
1,343
1,040
1,058
1,072
1,264
1,267
846
986
929
1,189
1,107
1,435
1,482
1,480
1,864
1,928
1,406
1,816
2,378
2,137
2,041
1,839
3,149
2,422
2,484
1,902
1,648
2,006
2,569
2,561
3,846
3,484
3,391
11,264
11,394
11,078
10,678
10,829
8,997
8,271
8,083
6,122
6,135
5,954
5,746
6,012
6,411
7,500
8,940
9,458
9,050
9,373
10,522
11,832
11,727
14,442
17,106
18,514
20,588
19,962
18,235
18,006
18,00618,23519,96220,58818,51417,10614,44211,72711,83210,5229,3739,0509,4588,9407,5006,4116,0125,7465,9546,1356,1228,0838,2718,99710,82910,67811,07811,39411,2643,3913,4843,8462,5612,5692,0061,6481,9022,4842,4223,1491,8392,0412,1372,3781,8161,4061,9281,8641,4801,4821,4351,1071,1899299868461,2671,2641,0721,0581,0401,3431,7652,2772,4283,9331,5431,2841,2651,9151,8801,7398321,1041,1059336371,2209069087594773943724795213332733633423201814264003002002002003002003004003003003,3003,6005,100
       Cash And Cash Equivalents 
2,000
200
0
0
0
0
200
0
0
0
100
0
100
100
24
38
59
30
41
51
15
6
68
25
16
96
214
248
183
139
104
96
138
110
119
438
758
953
414
311
180
2,495
1,728
1,282
398
40
149
17
8
123
14
116
87
27
225
187
499
469
535
592
509
338
524
273
253
358
403
1,953
1,213
708
391
273
538
550
811
1,681
1,999
910
9,246
9,150
7,828
7,079
7,436
6,174
5,986
5,409
4,160
1,844
1,900
2,249
2,596
1,857
2,255
4,267
6,118
5,369
5,239
7,269
7,410
7,781
8,782
11,368
12,910
13,811
12,563
11,306
11,356
11,35611,30612,56313,81112,91011,3688,7827,7817,4107,2695,2395,3696,1184,2672,2551,8572,5962,2491,9001,8444,1605,4095,9866,1747,4367,0797,8289,1509,2469101,9991,6818115505382733917081,2131,953403358253273524338509592535469499187225278711614123817149403981,2821,7282,4951803114149537584381191101389610413918324821496162568615514130593824100100010000020000002002,000
       Net Receivables 
1,300
1,200
1,100
200
200
300
100
100
200
100
100
100
200
200
318
70
169
239
211
80
132
403
284
275
260
313
468
514
480
816
132
375
468
597
376
982
872
704
432
634
980
958
248
708
956
766
398
552
592
592
697
151
271
409
515
570
445
341
245
465
479
281
254
453
688
501
495
530
585
943
570
634
487
841
618
663
203
1,404
1,068
688
1,211
1,505
1,341
1,460
838
1,504
741
3,062
2,560
2,243
2,374
3,706
3,995
3,149
1,981
2,122
2,937
1,847
2,756
2,139
3,617
3,451
2,991
2,885
2,966
1,641
1,065
1,0651,6412,9662,8852,9913,4513,6172,1392,7561,8472,9372,1221,9813,1493,9953,7062,3742,2432,5603,0627411,5048381,4601,3411,5051,2116881,0681,40420366361884148763457094358553049550168845325428147946524534144557051540927115169759259255239876695670824895898063443270487298237659746837513281648051446831326027528440313280211239169703182002001001001002001001003002002001,1001,2001,300
       Inventory 
1,500
1,700
1,400
0
0
0
0
0
0
100
0
0
100
200
79
64
84
67
82
87
129
44
53
57
99
60
54
116
104
173
364
345
313
270
232
228
184
190
171
160
249
214
159
157
314
460
406
407
389
477
449
517
553
427
377
279
412
552
596
691
810
691
901
790
476
655
456
324
370
623
886
679
871
1,056
1,015
1,242
1,140
960
822
1,183
1,249
1,368
1,117
1,085
1,097
881
819
711
969
903
969
669
1,017
1,261
1,192
1,210
999
1,168
1,532
1,645
1,745
2,116
2,460
3,757
4,246
5,145
5,371
5,3715,1454,2463,7572,4602,1161,7451,6451,5321,1689991,2101,1921,2611,0176699699039697118198811,0971,0851,1171,3681,2491,1838229601,1401,2421,0151,056871679886623370324456655476790901691810691596552412279377427553517449477389407406460314157159214249160171190184228232270313345364173104116546099575344129878267846479200100001000000001,4001,7001,500
       Other Current Assets 
300
500
800
100
100
100
0
100
100
0
0
100
-100
-100
5
9
8
6
29
55
56
69
74
15
19
8
22
30
62
92
38
50
125
75
105
91
66
68
247
179
134
266
294
130
97
77
86
83
83
72
106
62
75
66
72
70
80
120
105
115
130
96
138
862
720
526
486
342
254
209
55
62
109
122
117
260
141
117
129
372
790
725
936
278
349
290
402
518
525
352
73
179
233
262
166
349
199
237
134
163
298
170
154
135
187
144
214
21414418713515417029816313423719934916626223317973352525518402290349278936725790372129117141260117122109625520925434248652672086213896130115105120807072667562106728383867797130294266134179247686691105751255038926230228191574695655296895-100-100100001001000100100100800500300
   > Long-term Assets 
40,300
31,400
31,300
12,800
12,600
12,700
6,300
300
300
300
300
100
100
100
119
114
107
101
95
101
95
92
86
274
386
380
360
347
345
360
600
784
755
719
678
680
654
628
721
778
818
1,413
2,024
2,310
2,433
2,389
2,358
2,230
2,149
2,068
2,003
1,925
1,841
1,754
1,694
1,713
1,685
1,621
1,581
2,307
2,337
2,315
2,273
1,508
1,476
1,418
1,403
1,948
3,314
4,682
5,256
6,035
6,334
7,002
8,363
11,857
13,112
13,988
14,908
14,998
15,674
16,346
16,522
18,811
19,021
19,303
19,506
19,189
22,055
21,611
21,465
20,858
20,418
19,975
19,697
20,174
20,056
19,610
19,357
18,801
18,080
17,662
17,273
17,146
16,686
16,247
15,938
15,93816,24716,68617,14617,27317,66218,08018,80119,35719,61020,05620,17419,69719,97520,41820,85821,46521,61122,05519,18919,50619,30319,02118,81116,52216,34615,67414,99814,90813,98813,11211,8578,3637,0026,3346,0355,2564,6823,3141,9481,4031,4181,4761,5082,2732,3152,3372,3071,5811,6211,6851,7131,6941,7541,8411,9252,0032,0682,1492,2302,3582,3892,4332,3102,0241,413818778721628654680678719755784600360345347360380386274869295101951011071141191001001003003003003006,30012,70012,60012,80031,30031,40040,300
       Property Plant Equipment 
8,500
8,400
8,400
200
200
100
100
100
100
100
100
100
100
100
119
114
107
101
95
101
95
92
86
274
386
380
360
347
345
360
600
784
729
704
674
680
654
628
721
611
594
1,222
1,805
2,260
2,383
2,309
2,278
2,200
2,119
2,040
1,976
1,898
1,815
1,728
1,669
1,689
1,661
1,599
1,559
1,521
1,507
1,487
1,448
1,434
1,404
1,348
1,335
1,853
3,221
4,608
5,182
5,962
6,261
6,929
8,291
9,869
11,378
13,048
13,981
14,325
15,006
15,739
15,915
17,380
17,593
17,899
18,118
17,948
20,814
20,371
20,226
19,764
19,325
18,883
18,606
18,591
18,474
18,029
17,777
17,500
17,219
16,802
16,413
16,202
15,742
15,304
14,996
14,99615,30415,74216,20216,41316,80217,21917,50017,77718,02918,47418,59118,60618,88319,32519,76420,22620,37120,81417,94818,11817,89917,59317,38015,91515,73915,00614,32513,98113,04811,3789,8698,2916,9296,2615,9625,1824,6083,2211,8531,3351,3481,4041,4341,4481,4871,5071,5211,5591,5991,6611,6891,6691,7281,8151,8981,9762,0402,1192,2002,2782,3092,3832,2601,8051,222594611721628654680674704729784600360345347360380386274869295101951011071141191001001001001001001001001002002008,4008,4008,500
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
219
219
219
219
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000021921921921900000000000000000000000000000000000000000000000000000000000000000000000000000000000
       Intangible Assets 
31,600
22,700
22,700
6,000
6,000
6,000
6,000
200
200
200
200
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
30
30
29
28
27
26
26
25
24
23
23
22
36
79
77
76
74
72
70
68
66
64
38
37
36
36
35
34
33
33
32
31
30
30
29
28
517
502
486
471
24
24
23
22
21
21
20
19
19
18
17
16
16
15
14
13
13
12
11
10
10111213131415161617181919202121222324244714865025172829303031323333343536363738646668707274767779362223232425262627282930300000000000000000000000000000000000002002002002006,0006,0006,0006,00022,70022,70031,600
       Long-term Assets Other 
200
300
200
6,600
6,400
6,600
200
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
26
15
4
0
0
0
0
168
224
191
219
50
50
80
80
0
0
0
0
0
0
0
0
0
0
0
0
750
750
750
750
0
0
0
0
29
29
37
37
37
37
39
39
93
93
94
91
91
91
578
578
696
707
699
699
696
696
696
696
693
693
693
693
690
690
690
690
846
846
846
846
932
932
932
932
932932932932846846846846690690690690693693693693696696696696699699707696578578919191949393393937373737292900007507507507500000000000008080505021919122416800004152600000000000000000000000002006,6006,4006,600200300200
> Total Liabilities 
10,100
10,600
12,200
3,700
3,800
4,100
1,800
1,600
1,800
1,700
1,900
2,200
2,500
2,700
2,815
2,685
2,675
1,922
1,605
1,511
1,510
1,612
1,348
1,298
1,383
1,116
849
873
731
1,112
1,113
1,604
1,687
1,550
1,233
1,958
2,114
2,121
1,660
1,759
2,068
2,831
2,406
3,034
3,211
3,820
3,936
5,219
5,034
4,171
4,091
4,143
4,226
3,823
3,606
3,372
3,394
3,248
3,304
3,653
3,743
3,352
3,843
3,872
3,169
3,253
2,904
4,853
5,256
5,927
5,214
5,591
6,025
6,483
6,709
7,827
7,440
6,473
5,146
3,991
3,614
3,351
3,287
5,264
4,858
5,071
2,914
2,110
5,332
5,172
5,358
4,957
4,386
4,292
4,322
4,914
4,578
4,599
4,772
3,331
3,313
3,812
3,921
5,445
4,607
3,538
3,981
3,9813,5384,6075,4453,9213,8123,3133,3314,7724,5994,5784,9144,3224,2924,3864,9575,3585,1725,3322,1102,9145,0714,8585,2643,2873,3513,6143,9915,1466,4737,4407,8276,7096,4836,0255,5915,2145,9275,2564,8532,9043,2533,1693,8723,8433,3523,7433,6533,3043,2483,3943,3723,6063,8234,2264,1434,0914,1715,0345,2193,9363,8203,2113,0342,4062,8312,0681,7591,6602,1212,1141,9581,2331,5501,6871,6041,1131,1127318738491,1161,3831,2981,3481,6121,5101,5111,6051,9222,6752,6852,8152,7002,5002,2001,9001,7001,8001,6001,8004,1003,8003,70012,20010,60010,100
   > Total Current Liabilities 
4,700
5,300
7,200
3,400
2,800
3,100
1,700
1,500
1,700
1,700
1,800
2,100
1,900
2,700
2,754
2,212
1,834
948
676
624
814
908
732
622
758
590
550
622
507
917
844
1,066
1,145
1,003
707
736
896
924
470
644
978
1,242
825
852
1,061
1,722
2,108
3,448
3,330
2,513
2,481
2,119
2,240
1,873
1,637
1,927
1,735
1,643
1,658
1,510
2,503
2,142
2,623
2,566
1,875
1,962
1,817
2,213
2,357
2,792
2,318
2,965
2,544
2,811
3,040
5,203
5,001
4,461
3,361
2,534
2,367
2,148
1,789
4,067
3,875
4,193
2,137
1,360
1,648
1,597
1,861
1,741
1,236
1,208
1,306
1,391
1,126
1,219
1,465
972
850
917
842
2,101
1,465
811
1,637
1,6378111,4652,1018429178509721,4651,2191,1261,3911,3061,2081,2361,7411,8611,5971,6481,3602,1374,1933,8754,0671,7892,1482,3672,5343,3614,4615,0015,2033,0402,8112,5442,9652,3182,7922,3572,2131,8171,9621,8752,5662,6232,1422,5031,5101,6581,6431,7351,9271,6371,8732,2402,1192,4812,5133,3303,4482,1081,7221,0618528251,2429786444709248967367071,0031,1451,0668449175076225505907586227329088146246769481,8342,2122,7542,7001,9002,1001,8001,7001,7001,5001,7003,1002,8003,4007,2005,3004,700
       Short-term Debt 
3,400
3,200
3,800
1,100
500
600
400
300
200
0
300
500
200
800
25
326
80
83
84
82
83
84
85
169
139
116
103
86
81
89
186
168
161
135
125
115
102
94
163
73
62
87
79
113
111
128
130
132
133
135
148
139
141
143
133
614
623
631
643
154
1,043
1,005
966
169
171
172
174
573
687
805
833
841
878
977
1,055
1,930
1,957
1,981
2,023
1,075
1,055
1,210
983
934
886
746
581
410
551
529
505
450
408
365
357
323
335
361
367
290
294
303
313
370
381
386
391
3913863813703133032942903673613353233573654084505055295514105817468869349831,2101,0551,0752,0231,9811,9571,9301,0559778788418338056875731741721711699661,0051,0431546436316236141331431411391481351331321301281111137987627316394102115125135161168186898186103116139169858483828483803262580020050030002003004006005001,1003,8003,2003,400
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,532
2,303
2,087
983
934
886
746
581
410
296
271
243
185
140
93
81
72
75
78
81
0
0
0
0
0
0
0
0
000000008178757281931401852432712964105817468869349832,0872,3032,5320000000000000000000000000000000000000000000000000000000000000000000000000000000
       Accounts payable 
1,300
2,200
3,300
2,300
2,400
2,500
1,300
1,300
1,500
1,500
1,500
1,600
1,700
1,600
1,657
1,752
1,621
741
572
522
711
804
627
454
619
475
448
536
427
665
559
713
840
690
408
285
473
674
259
336
658
888
404
494
667
481
628
1,606
1,706
1,574
1,731
0
0
1,620
0
1,240
0
353
384
624
502
474
718
578
693
527
1,063
994
1,257
1,784
1,316
1,791
1,177
1,209
1,694
2,006
1,901
1,907
0
969
989
750
785
965
835
830
1,290
950
1,057
1,027
1,316
1,291
828
843
950
1,046
791
858
1,098
672
557
614
529
1,730
1,084
424
1,246
1,2464241,0841,7305296145576721,0988587911,0469508438281,2911,3161,0271,0579501,29083083596578575098996901,9071,9012,0061,6941,2091,1771,7911,3161,7841,2579941,06352769357871847450262438435301,24001,620001,7311,5741,7061,6066284816674944048886583362596744732854086908407135596654275364484756194546278047115225727411,6211,7521,6571,6001,7001,6001,5001,5001,5001,3001,3002,5002,4002,3003,3002,2001,300
       Other Current Liabilities 
0
-100
100
0
-100
0
0
-100
0
200
0
0
0
300
1,072
134
134
124
20
20
20
20
20
0
0
0
0
0
0
163
99
104
144
178
174
107
206
156
48
130
158
174
118
138
228
1,056
1,287
1,653
1,427
741
545
1,920
2,039
50
1,444
13
1,112
111
164
160
192
120
119
120
160
126
293
284
367
155
169
170
0
0
0
95
299
201
1,056
490
1,029
750
785
3,133
2,989
464
1,290
950
1,097
1,067
1,356
1,291
828
843
950
1,068
791
858
1,098
682
557
614
529
1,730
1,084
424
1,246
1,2464241,0841,7305296145576821,0988587911,0689508438281,2911,3561,0671,0979501,2904642,9893,1337857501,0294901,056201299950001701691553672842931261601201191201921601641111,112131,444502,0391,9205457411,4271,6531,2871,056228138118174158130481562061071741781441049916300000020202020201241341341,0723000002000-10000-1000100-1000
   > Long-term Liabilities 
5,400
5,300
5,000
300
1,000
1,000
100
100
100
100
100
100
600
100
61
473
841
974
929
887
696
705
616
676
625
526
298
251
223
196
269
538
542
547
526
1,221
1,218
1,197
1,190
1,115
1,090
1,589
1,582
2,182
2,149
2,098
1,828
1,770
1,704
1,658
1,610
2,025
1,987
1,950
1,969
1,445
1,658
1,605
1,646
2,143
1,240
1,211
1,220
1,306
1,294
1,291
1,086
2,640
2,899
3,136
2,896
2,626
3,481
3,672
3,668
2,624
2,439
2,013
1,785
1,457
1,248
1,203
1,497
1,197
983
879
777
750
3,684
3,575
3,497
3,216
3,150
3,083
3,016
3,523
3,452
3,380
3,307
2,359
2,463
2,895
3,079
3,345
3,142
2,728
2,343
2,3432,7283,1423,3453,0792,8952,4632,3593,3073,3803,4523,5233,0163,0833,1503,2163,4973,5753,6847507778799831,1971,4971,2031,2481,4571,7852,0132,4392,6243,6683,6723,4812,6262,8963,1362,8992,6401,0861,2911,2941,3061,2201,2111,2402,1431,6461,6051,6581,4451,9691,9501,9872,0251,6101,6581,7041,7701,8282,0982,1492,1821,5821,5891,0901,1151,1901,1971,2181,221526547542538269196223251298526625676616705696887929974841473611006001001001001001001001,0001,0003005,0005,3005,400
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
326
634
605
541
506
442
524
524
524
524
379
379
379
379
874
874
874
874
0
179
693
959
0
0
675
0
0675009596931790874874874874379379379379524524524524442506541605634326000000000000000000000000000000000000000000000000000000000000000000000000000000000
> Total Stockholder Equity
35,300
24,400
22,400
9,400
9,100
9,000
4,800
-1,100
-1,200
-1,200
-1,400
-1,900
-2,100
-2,200
-2,269
-2,391
-2,248
-1,479
-1,147
-1,137
-1,083
-999
-782
-653
-603
-259
271
382
521
468
124
114
173
273
277
461
420
421
325
304
293
2,515
2,046
1,554
987
-88
-537
-1,931
-1,813
-839
-820
-1,373
-1,399
-1,140
-722
-552
-274
-145
-243
518
521
368
246
14
443
206
338
244
480
1,239
1,944
2,092
2,314
3,088
4,216
7,877
9,156
10,906
21,026
22,401
23,138
23,673
24,064
22,544
22,434
22,315
22,713
23,215
22,677
22,186
22,119
22,312
23,532
24,623
24,833
24,310
24,851
25,534
26,417
27,197
29,209
30,956
31,866
32,289
32,040
30,944
29,963
29,96330,94432,04032,28931,86630,95629,20927,19726,41725,53424,85124,31024,83324,62323,53222,31222,11922,18622,67723,21522,71322,31522,43422,54424,06423,67323,13822,40121,02610,9069,1567,8774,2163,0882,3142,0921,9441,23948024433820644314246368521518-243-145-274-552-722-1,140-1,399-1,373-820-839-1,813-1,931-537-889871,5542,0462,515293304325421420461277273173114124468521382271-259-603-653-782-999-1,083-1,137-1,147-1,479-2,248-2,391-2,269-2,200-2,100-1,900-1,400-1,200-1,200-1,1004,8009,0009,1009,40022,40024,40035,300
   Common Stock
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
6,316
0
6,316
0
0
0
0
0
0
0
0
0
0
0
0
0
14,859
15,419
15,517
15,535
15,566
15,671
15,671
16,321
16,321
16,323
16,342
16,402
16,402
16,503
16,503
16,508
16,511
16,550
16,556
16,557
16,557
16,558
16,657
16,685
16,695
16,698
16,698
16,722
16,72216,69816,69816,69516,68516,65716,55816,55716,55716,55616,55016,51116,50816,50316,50316,40216,40216,34216,32316,32116,32115,67115,67115,56615,53515,51715,41914,85900000000000006,31606,316000000000000000000000000000000000000000000000000000000000000000
   Retained Earnings 
-12,900
-15,000
-17,100
-30,700
-31,000
-31,100
-38,500
-44,900
-45,000
-45,100
-45,300
-45,800
-46,000
-46,200
-46,287
-46,720
-46,857
-47,136
-47,241
-47,099
-47,232
-47,146
-2,112
-2,048
-2,018
-1,798
-1,467
-1,606
-1,493
-1,564
-1,926
-2,003
-2,160
-2,058
-2,183
-2,060
-2,112
-2,115
-2,211
-2,333
-2,354
-2,592
-3,194
-3,722
-4,331
-5,418
-5,906
-7,322
-7,219
-6,753
-6,756
-7,391
-7,440
-7,202
-7,088
-6,890
-6,620
-6,515
-6,623
-6,196
-6,199
-6,360
-6,496
-6,734
-6,326
-6,578
-6,454
-6,558
-6,381
-5,751
-5,061
-4,964
-5,175
-4,518
-3,511
-59
1,154
2,790
3,435
3,667
3,685
4,055
4,351
2,709
2,413
2,248
1,949
2,393
1,756
1,198
1,094
1,260
2,386
3,464
3,655
3,117
3,631
4,308
5,183
5,959
7,955
9,618
10,479
10,880
10,495
9,341
8,300
8,3009,34110,49510,88010,4799,6187,9555,9595,1834,3083,6313,1173,6553,4642,3861,2601,0941,1981,7562,3931,9492,2482,4132,7094,3514,0553,6853,6673,4352,7901,154-59-3,511-4,518-5,175-4,964-5,061-5,751-6,381-6,558-6,454-6,578-6,326-6,734-6,496-6,360-6,199-6,196-6,623-6,515-6,620-6,890-7,088-7,202-7,440-7,391-6,756-6,753-7,219-7,322-5,906-5,418-4,331-3,722-3,194-2,592-2,354-2,333-2,211-2,115-2,112-2,060-2,183-2,058-2,160-2,003-1,926-1,564-1,493-1,606-1,467-1,798-2,018-2,048-2,112-47,146-47,232-47,099-47,241-47,136-46,857-46,720-46,287-46,200-46,000-45,800-45,300-45,100-45,000-44,900-38,500-31,100-31,000-30,700-17,100-15,000-12,900
   Capital Surplus 00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Treasury Stock00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
48,200
39,400
39,500
40,100
40,100
40,100
43,300
43,800
43,800
43,900
43,900
43,900
43,900
44,000
44,018
44,329
44,609
45,658
46,095
45,962
46,149
46,147
1,330
1,395
1,415
1,539
1,738
1,988
2,013
2,033
2,049
1,995
2,212
2,209
2,338
2,522
2,532
2,536
2,536
2,637
2,648
5,106
5,240
5,276
5,318
5,330
5,368
5,390
5,405
5,914
5,936
6,018
6,040
6,062
6,365
6,338
6,347
6,370
6,380
6,713
6,721
6,728
6,743
432
6,786
485
6,810
6,820
6,878
7,007
7,022
7,073
7,489
7,606
7,727
7,936
8,002
8,116
17,591
18,734
19,454
19,618
19,713
19,835
20,020
20,067
20,764
4,501
20,921
4,646
4,623
4,650
4,642
4,657
4,670
4,682
4,669
4,670
4,676
4,681
4,695
4,681
4,701
4,714
4,847
4,906
4,941
4,9414,9064,8474,7144,7014,6814,6954,6814,6764,6704,6694,6824,6704,6574,6424,6504,6234,64620,9214,50120,76420,06720,02019,83519,71319,61819,45418,73417,5918,1168,0027,9367,7277,6067,4897,0737,0227,0076,8786,8206,8104856,7864326,7436,7286,7216,7136,3806,3706,3476,3386,3656,0626,0406,0185,9365,9145,4055,3905,3685,3305,3185,2765,2405,1062,6482,6372,5362,5362,5322,5222,3382,2092,2121,9952,0492,0332,0131,9881,7381,5391,4151,3951,33046,14746,14945,96246,09545,65844,60944,32944,01844,00043,90043,90043,90043,90043,80043,80043,30040,10040,10040,10039,50039,40048,200



Balance Sheet

Currency in CAD. All numbers in thousands.




Cash Flow

Currency in CAD. All numbers in thousands.




Income Statement

Currency in CAD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue11,305
Cost of Revenue-6,345
Gross Profit4,9604,960
 
Operating Income (+$)
Gross Profit4,960
Operating Expense-15,160
Operating Income-3,855-10,200
 
Operating Expense (+$)
Research Development2,660
Selling General Administrative6,155
Selling And Marketing Expenses-
Operating Expense15,1608,815
 
Net Interest Income (+$)
Interest Income-
Interest Expense-131
Other Finance Cost-55
Net Interest Income-186
 
Pretax Income (+$)
Operating Income-3,855
Net Interest Income-186
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-3,569-4,327
EBIT - interestExpense = -131
-2,810
-2,679
Interest Expense131
Earnings Before Interest and Taxes (EBIT)--3,438
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax-3,569
Tax Provision--759
Net Income From Continuing Ops-2,810-2,810
Net Income-2,810
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net472186
 

Technical Analysis of Ceapro
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Ceapro. The general trend of Ceapro is BULLISH with 28.6% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Ceapro's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (28.6%) Bearish trend (-28.6%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Ceapro.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 0.26 < 0.27 < 0.27.

The bearish price targets are: 0.24 > 0.23 > 0.23.

Tweet this
Ceapro Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Ceapro. The current mas is .

The long score for the Moving Averages is 9/14.
The longshort score for the Moving Averages is 4/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Ceapro Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Ceapro. The current macd is 0.00415969.

The long score for the Moving Average Convergence/Divergence (MACD) is 2/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 0/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Ceapro price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Ceapro. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Ceapro price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Ceapro Daily Moving Average Convergence/Divergence (MACD) ChartCeapro Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Ceapro. The current adx is 15.77.

The long score for the Directional Movement Index (DMI) is 2/7.
The longshort score for the Directional Movement Index (DMI) is 2/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Ceapro shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bullish trend could be forming. +1
Ceapro Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Ceapro. The current sar is 0.23.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Ceapro Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Ceapro. The current rsi is 62.12. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending up: The RSI is trending up. +1
Ceapro Daily Relative Strength Index (RSI) ChartCeapro Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Ceapro. The current phase is Overbought in bull market.

The long score for the Stochastic Oscillator is 6/6.
The longshort score for the Stochastic Oscillator is 6/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH > 80: The STOCH %K is above 80 and overbought. +2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Ceapro price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Ceapro Daily Stochastic Oscillator ChartCeapro Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Ceapro. The current cci is 96.36.

Ceapro Daily Commodity Channel Index (CCI) ChartCeapro Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Ceapro. The current cmo is 33.29.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Ceapro Daily Chande Momentum Oscillator (CMO) ChartCeapro Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Ceapro. The current willr is 0.

The long score for the Williams %R is 1/1.
The longshort score for the Williams %R is 1/(-1 +1).

  • WILLR > -20: The Williams %R is above -20. This indicates that the price is in overbought territory, suggesting a potential price correction or trend reversal to the downside. +1
Ceapro Daily Williams %R ChartCeapro Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Ceapro.

Ceapro Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Ceapro. The current atr is 0.00750048.

Ceapro Daily Average True Range (ATR) ChartCeapro Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Ceapro. The current obv is -2,807,500.

Ceapro Daily On-Balance Volume (OBV) ChartCeapro Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Ceapro. The current mfi is 69.04.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Ceapro Daily Money Flow Index (MFI) ChartCeapro Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Ceapro.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-04CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-05STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-06STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-07STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-12STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-13DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2023-12-14SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2023-12-18DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-20MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2023-12-22BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2023-12-29STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-02BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-03RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-11MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-01-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-17CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-19RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-01-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-24CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-29SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-30CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-31STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-01ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-02STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-05STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-06SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-08SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-09CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-13CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-16STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-21ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-22STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-23DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-26RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-27MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-01CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-14STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-15STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-21MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-25STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-26STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-27MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-01CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-02SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-03STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-08CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-04-10MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-15MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-04-16DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-18DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-19DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-22CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-23WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-26DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).

6.3. Candlestick Patterns

Ceapro Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Ceapro based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5062.119
Ma 20Greater thanMa 500.246
Ma 50Greater thanMa 1000.231
Ma 100Greater thanMa 2000.213
OpenGreater thanClose0.245
Total3/5 (60.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Ceapro with someone you think should read this too:
  • Are you bullish or bearish on Ceapro? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Ceapro? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Ceapro

I send you an email if I find something interesting about Ceapro.


Comments

How you think about this?

Leave a comment

Stay informed about Ceapro.

Receive notifications about Ceapro in your mailbox!